Tozy

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tozy

What is Tozy? Foundational Definition

Property Description
Active ingredients Acetaminophen (Paracetamol) and Caffeine
Form Oral tablets
Pharmacological class Non-opioid analgesic and CNS stimulant combination
General purpose Relief of mild to moderate pain and fever
Origin Synthetic and naturally-derived components

The preparation Tozy is classified as a fixed-dose combination product within the therapeutic groups of non-opioid analgesics and central nervous system (CNS) stimulants. This formulation, which is typically presented as oral tablets, incorporates two distinct active ingredients to achieve a robust combined effect. Tozy is broadly available as an over-the-counter (OTC) medicine, making it a readily accessible choice for general symptomatic relief.

Composition and Active Ingredients

The active ingredients in Tozy are Acetaminophen and Caffeine. Acetaminophen, the primary agent, is a synthetic compound that is clinically recognized for its established analgesic and antipyretic properties. The Caffeine component, a naturally-derived methylxanthine, acts as an adjunctive agent. This dual composition, utilizing both a synthetic compound and a naturally-derived stimulant, is a common feature in formulations targeting temporary relief from symptoms such as tension discomfort.

The Principle of Dual-Action Relief

The rationale for the combination in Tozy is the established synergistic effect achieved when Acetaminophen is administered alongside Caffeine. Acetaminophen manages the core pain and fever symptoms centrally. The addition of Caffeine enhances the pain-relieving action of the analgesic component; this stimulant improves the efficacy profile of the non-opioid component. This combination approach aims to optimize symptomatic comfort by providing both direct relief and a potentiated therapeutic outcome through the increased proportion of individuals who achieve effective pain relief.

Regulatory References

  1. National Institutes of Health (NIH)

What side effects are possible with Tozy?

Possible Side Effects and Safety Information

The safety profile for Tozy, a fixed-dose combination of Acetaminophen (Paracetamol) and Caffeine, is defined by regulatory documents that list adverse reactions by frequency and affected organ system. This section details the officially documented effects and safety constraints, without providing usage instructions or advice.

Documented Adverse Reactions

The adverse reactions are categorized based on regulatory frequency data. Classifications may vary by region.

Frequency Classification Examples of Officially Listed Effects
Very Rare (≤ 1/10,000) Thrombocytopenia, Agranulocytosis (blood disorders), Anaphylaxis, Hepatic dysfunction, Severe Cutaneous Adverse Reactions (SJS, TEN, AGEP).
Not Known (Frequency undetermined) Insomnia, Nervousness, Restlessness, Palpitations, Tachycardia, Dizziness, Nausea.

Serious adverse reactions explicitly cited in regulatory labeling include Acute Liver Failure (associated with Acetaminophen, particularly in overdose) and Severe Skin Reactions (such as SJS, TEN, and AGEP). These events are generally classified as Very Rare.

Official Safety Constraints and Special Populations

The regulatory safety documentation includes specific limitations and warnings for certain patient groups and conditions:

  • Hepatic and Renal Impairment: Use is cautioned in individuals with pre-existing liver disease or severe kidney impairment, as these conditions increase the risk of adverse events.
  • Cardiovascular Conditions: Use is restricted in patients with diagnosed hypertension or severe cardiac arrhythmia due to the stimulant effects of Caffeine.
  • Pregnancy and Lactation: The medication is generally not recommended during pregnancy due to the potential risk associated with the Caffeine component. Caffeine is excreted into breast milk and may cause stimulating effects in the infant.
  • Dietary Caffeine: Official labeling advises against consuming excessive amounts of dietary caffeine (e.g., from coffee or soft drinks) while using the product to prevent increased stimulant-related adverse effects like jitteriness and anxiety.

These constraints outline the official regulatory boundaries for the use of this medication.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Tozy (metformin) carries a major, life-threatening risk of lactic acidosis, which is considered a medical emergency with a high mortality rate. Lactic acidosis is the principal, most severe complication of overexposure, particularly in individuals with reduced kidney function.

Documented Overdose Symptoms

Symptoms of overdose often begin with significant gastrointestinal distress, including nausea, vomiting, diarrhea, and severe abdominal pain. These symptoms can progress to systemic signs of severe intoxication, which include extreme tiredness, unusual muscle pain, and deep, rapid breathing (a hallmark sign of acidosis). In severe cases, low blood sugar (hypoglycemia) may occur, and the intoxication can lead to life-threatening complications such as cardiovascular collapse, seizures, and coma.

Emergency Action Required

Due to the risk of potentially fatal lactic acidosis, immediate emergency medical attention is required for any suspected overdose. Emergency services should be contacted immediately if a person exhibits symptoms such as difficulty breathing, severe weakness, unusual muscle pain, or an inability to be roused. In a clinical setting, treatment for severe overdose involves supportive care, correction of the acidosis, and rapid removal of the drug from the body, typically achieved through hemodialysis.

Therapeutic Uses of Tozy

What Tozy Treats: Main Uses and Benefits

The primary therapeutic role of Tozy, an analgesic and antipyretic combination, is for symptomatic relief in acute situations. The medication is used across conditions presenting with both pain and fever, providing support that helps ease the overall symptom burden.

Tozy is applied in contexts where short-term symptomatic assistance is needed for acute or disruptive symptom patterns, such as tension-type headaches, episodes of acute migraine attacks, general muscle aches, toothaches, menstrual cramps (dysmenorrhea), and the fever and body aches associated with common cold or flu. This supports general well-being during symptomatic periods.

“The formulation is relevant when supportive symptom management is appropriate for symptoms that create noticeable physiological strain.”

It is relevant for easing symptoms that are classified as mild to moderate. This contributes to easing the overall symptom load and may assist with maintaining comfort during periods of heightened symptoms.


Quick Fact: Relief for Acute Episodic Discomfort

Regulatory References

  1. Philippine FDA guidelines

Eligibility and Restrictions for Use

The eligibility for using Tozy (an Acetaminophen and Caffeine combination) is strictly defined by regulatory authorities based on age, physiological status, and underlying health conditions. The official labeling specifies groups for whom use is permitted, restricted, or absolutely prohibited (contraindicated).

Eligibility scope

Scope Classification Regulatory Statement
Populations for whom use is allowed Adults and adolescents 12 years of age and older.
Populations for whom use is not recommended Children younger than 12 years of age, and individuals who are breastfeeding.
Populations for whom use is contraindicated Individuals with known hypersensitivity to any component or patients with Porphyria.

Age-related and Condition-specific Eligibility

Age-related eligibility rules state that use is not established and should not be used in children younger than 12. Condition-specific eligibility rules require use with caution in patients with liver disease or kidney disease, particularly in severe cases, as the drug’s components are eliminated via these organs.

Eligibility classifications (high-level)

Classification Eligibility-context Constraints
Contraindicated Absolute prohibition for hypersensitivity and certain severe systemic conditions.
Not Recommended Status for breastfeeding individuals and children under 12.
Use with Caution Status for individuals with a history of alcohol abuse or underlying hepatic/renal impairment.

Resulting eligibility structure

Official eligibility statements formally classify individuals with severe liver disease or hypersensitivity as contraindicated. The profile further places significant limitations on use during breastfeeding and for the pediatric population under 12.

What should I know about interactions with other medicines?

The official interaction profile for Tozy is defined by the regulatory data established for its two active ingredients, Acetaminophen and Caffeine, across two main domains: metabolic clearance and pharmacodynamic risk.

Contraindicated Combinations

Co-administration with Fezolinetant is strictly contraindicated, as the caffeine component interferes with the CYP1A2 metabolic enzyme, which significantly increases the exposure and concentration of Fezolinetant. Likewise, drugs in the Monoamine Oxidase Inhibitor (MAOI) class, such as Isocarboxazid and Linezolid, are formally prohibited due to the risk of an acute hypertensive episode resulting from a pharmacodynamic interaction with caffeine.

Pharmacokinetic and Substance Restrictions

Certain agents that reduce caffeine elimination, such as Cimetidine and Ketoconazole, may increase the plasma concentration of the caffeine component. Separately, the regulatory label notes that chronic daily use of the acetaminophen component, especially at high doses (e.g., 4,000 mg/day), may increase the International Normalized Ratio (INR) of oral anticoagulants like Warfarin. Furthermore, the official label requires the temporary discontinuation of caffeine-containing products before administering diagnostic agents (e.g., Dipyridamole) due to a risk of pharmacodynamic antagonism.

A crucial restriction is placed on co-use with alcohol (ethanol), as regulatory documents state that consumption of three or more alcoholic drinks per day significantly increases the risk of severe liver damage. The acetaminophen component is also formally contraindicated in patients with severe hepatic impairment or active liver disease, as this condition elevates toxicity risk and reduces clearance.

Mechanism of Action

Tozy is a combination pharmaceutical product comprising Piperacillin, a beta-lactam antibiotic, and Tazobactam, a beta-lactamase inhibitor. Piperacillin exerts its action by covalently binding to and inactivating bacterial penicillin-binding proteins (PBPs), which are integral transpeptidases essential for the final cross-linking stage of peptidoglycan synthesis. This inhibition prevents cell wall construction, leading to a compromised cell wall structure and subsequent loss of cellular integrity. Tazobactam functions as a competitive and irreversible inhibitor of beta-lactamase enzymes. These bacterial enzymes hydrolyze the beta-lactam ring of Piperacillin, rendering it inactive. By forming a stable complex with beta-lactamase, Tazobactam protects Piperacillin from enzymatic degradation. This molecular interaction restores Piperacillin’s capacity to inhibit bacterial cell wall biosynthesis. The synergistic mechanism consequently expands the spectrum of microorganisms susceptible to the combination, modulating the systemic bacterial load by inhibiting proliferation and inducing structural failure in targeted microorganisms.

Dosage and Administration Information

How to use Tozy

The administration of Tozy, a fixed-dose combination product containing Acetaminophen 500 mg and Caffeine 65 mg, is governed by standardized guidelines. The protocol defines the route, maximum quantity, and time intervals between doses to ensure appropriate short-term use.


Administration Scope

Element Instruction
Route of administration The product is for oral administration.
Dosing schedule (Adults/Elderly) Take 2 tablets per dose. The dose must not exceed 8 tablets in any 24-hour period.
Minimum Dosing Interval A minimum of 4 hours must elapse between consecutive doses.
Age-group administration rules Adolescents (12–15 years): Take 1 tablet per dose, up to a maximum of 4 tablets in 24 hours. Use is not recommended for children under 12 years of age.
Duration Limit Use is limited to a maximum of 3 days for fever and 5 days for pain without consulting a physician.

Resulting Procedural Structure

Step sequence:

  • Swallow the tablet(s) whole with water; the tablets are not intended to be crushed or chewed.
  • Observe the minimum 4-hour interval between doses to prevent exceeding the maximum daily intake.
  • Avoid excessive caffeine from other dietary sources while utilizing this product.

Connection to the overall use protocol:

The instructions establish a standardized method of administration where the product must be swallowed whole via the oral route. This protocol is defined by two critical constraints: a maximum daily quantity that mandates a 4-hour minimum interval between doses, and a fixed short-term limit on the total course duration. These rules structure the frequency and amount of medicine taken, ensuring adherence to the labeled parameters across different use sessions.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Tozy

This section summarizes the published research base for the combination of Acetaminophen and Caffeine (the active ingredients in Tozy). The findings describe patterns observed in the studies and provide context regarding how symptoms were measured over defined time intervals. Research provides context but not individual predictions; the study results reflect the specific conditions under which they were conducted.

Research Supporting Symptom Relief for Acute Pain and Fever

Research primarily involves large-scale meta-analyses that pool data from multiple short-term randomized trials. These trials examined measurements of the proportion of individuals who met the study-defined primary endpoint during the study period, compared to the analgesic component alone or a placebo. The focus of the research was on outcomes related to physical discomfort in adult populations. Studies describe patterns observed where the addition of the caffeine component was studied alongside the analgesic component, and research highlights differences in the measured outcomes compared to the analgesic component alone. Research highlights changes measured during the study period, focusing on time frames typically up to four to six hours post-dosing, consistent with research scenarios observing responses over defined time intervals.

Studies on Acute Headache Management: Tension Headaches and Migraine

The research base was evaluated in randomized trials and systematic reviews that include individuals experiencing periods of heightened symptoms like tension-type headaches and acute migraine attacks. Researchers examined outcomes related to patient-reported experiences, such as achieving a pain-free status or a reduction of pain intensity, often measured at two hours post-dose. Studies exploring short-term symptom changes observed the use of rescue medication and changes in outcomes reflecting daily functioning or activity level during the acute episode. Findings indicate that the combination was studied for use in research contexts involving fluctuating or unstable symptoms.

Key Limitations and Uncertainty in the Evidence

Research highlights that studies focusing on episodes where symptoms become more noticeable tend to have follow-up durations that were limited to the acute phase. Consequently, long-term effects are not fully established, and certainty remains low for effects beyond the immediate, acute treatment window. Data for certain groups, such as children, the elderly, or individuals with severe underlying health conditions, remain insufficient. Results apply only to the populations studied, and extrapolation is not supported by the evidence.

Key Studies & References

  1. Acetaminophen (Oral Route) Overview
  2. Philippine Food and Drug Administration (FDA) Approved Product Information Leaflet (PIL) for Paracetamol and Caffeine combination

Frequently Asked Questions (FAQ)

Common questions about Tozy (FAQ)


Q: Why is Tozy prescribed instead of other medicines for the same condition?

A: Official information describes Tozy as a fixed-dose combination product containing Acetaminophen and Caffeine. The Caffeine component is documented as an adjunctive agent that is described in pharmacological studies as enhancing the pain-relieving action of the analgesic component. This combination approach is documented as the underlying principle for the combination.


Q: Can Tozy affect my sleep schedule?

A: Because Tozy contains Caffeine, a central nervous system (CNS) stimulant, official warnings indicate that excessive intake may cause side effects like nervousness, restlessness, and sleeplessness (insomnia). Official safety information cautions against excessive consumption of dietary caffeine from sources like coffee while using the product.


Q: Is Tozy known to cause weight gain?

A: In the official adverse reaction data compiled for the active ingredients in Tozy, weight gain is not listed as a commonly reported side effect or an adverse event of undetermined frequency. This means that regulatory documents do not identify weight gain as a known side effect of this medicine.


Q: Are there any long-term side effects of taking Tozy?

A: Regulatory documents explicitly limit the use of Tozy to a maximum of 3 days for fever and 5 days for pain without consulting a physician. The official labeling emphasizes that chronic daily use, particularly at high doses, may significantly increase the risk of severe events, such as Acute Liver Failure related to the Acetaminophen component. The duration limit on the label is consistent with short-term use.


Q: Do any foods or supplements need to be avoided while on Tozy?

A: Official regulatory documents caution against excessive intake of dietary caffeine (e.g., from coffee or energy drinks) due to the risk of increased stimulant-related adverse effects. Additionally, regulatory labels require caution regarding co-use with alcohol (ethanol), as consumption of three or more alcoholic drinks per day significantly increases the risk of severe liver damage.


Q: How long does it usually take for Tozy to start working?

A: Research trials summarized in regulatory documents examined symptom changes and pain relief outcomes over defined short-term intervals. These studies typically focused on time frames up to two to four hours post-dosing, which reflects the period when the onset of relief is commonly measured in an acute setting.


Q: Is Tozy safe to use during pregnancy?

A: The medication is generally not recommended during pregnancy due to the potential risk associated with the Caffeine component. For individuals who are breastfeeding, use is also not recommended because official documents state Caffeine is excreted into breast milk and may cause stimulating effects in the infant.


Q: What is the difference between Tozy and [Similar Drug Name]?

A: Official drug documentation and regulatory guidelines are focused exclusively on the approved drug product, Tozy, and its specific components, uses, and safety profile. Official sources do not provide comparative claims or analyses of differences between Tozy and other medicines.


Q: Is it true that Tozy can cause stomach issues?

A: Official adverse event listings, which categorize reactions by frequency, document Nausea as an effect of undetermined frequency ('Not Known'). Other general GI-related effects are sometimes noted in regulatory documents for combination products, indicating that some stomach issues are among the reported patient experiences.


Q: What kind of research has been done on Tozy?

A: The research base summarized in official documents primarily consists of large-scale meta-analyses and short-term randomized trials. These studies focused on measuring acute pain relief and changes in headache symptoms, such as achieving a pain-free status, over specified short time intervals.


Q: Is there a generic version of Tozy available?

A: Tozy is a brand name for a combination of Acetaminophen and Caffeine. Many generic drug products that contain this specific combination of active ingredients are available through regulatory approval processes, often under different names.


Q: What happens if I forget to take a dose of Tozy?

A: Official instructions for a missed dose advise patients to skip the missed dose and then continue with the regular dosing schedule. Official instructions specify that a double dose must be avoided, while strictly adhering to the minimum time interval between doses.


Q: Can Tozy be stopped suddenly, or does it need to be tapered?

A: Official drug labeling provides no specific requirements for tapering or gradually reducing the dose of Tozy upon discontinuation. Because the product is indicated for short-term, acute use, the regulatory documentation does not typically include a dose reduction protocol for stopping use.


Q: What should I do if a side effect of Tozy bothers me?

A: Official regulatory information mandates that patients report any side effects they experience. Regulatory guidelines note that patients are encouraged to consult with a doctor or pharmacist about any bothersome effects, and they should contact authorities if a serious side effect occurs.


Q: Are there common mental health side effects listed for Tozy?

A: Due to the Caffeine component, a CNS stimulant, officially listed adverse reactions of 'Not Known' frequency include effects such as Nervousness and Restlessness. These are the typical CNS-related effects documented in official safety information.


Q: Does taking Tozy affect my ability to drive or operate machinery?

A: Official safety warnings indicate that certain documented side effects, such as Dizziness and Nervousness, could potentially impair mental or physical abilities required for performing hazardous tasks. Regulatory warnings note that if these effects occur, they could potentially impair abilities, and this risk should be considered.


Q: Is Tozy addictive or habit-forming?

A: Official documentation for the Acetaminophen component indicates it is not associated with dependence. For the Caffeine component, official studies indicate that the occurrence of dependence or habituation is generally low when the product is used short-term as an analgesic adjuvant.


Q: What happens to Tozy after it is taken (metabolism)?

A: The drug's active components are primarily processed and broken down (metabolized) by the liver and then eliminated from the body via the kidneys. This is why regulatory labels include warnings and restrictions for patients with severe liver or kidney impairment, as these organs are vital for clearance.


Q: Does Tozy cause dizziness or lightheadedness?

A: Official adverse reaction listings document that Dizziness is an adverse event of undetermined frequency ('Not Known'). This effect, along with lightheadedness, has been noted in product information.


Q: Why do official sources list so many possible side effects for Tozy?

A: Regulatory agencies require manufacturers to list all adverse events observed in clinical trials and those reported post-marketing, even if a direct cause-and-effect relationship to the drug has not been definitively proven. The list is comprehensive to ensure patients are fully informed of all documented observations.


Q: Has Tozy been approved in countries outside the US?

A: The specific combination of Acetaminophen and Caffeine is a widely recognized formulation. Analogous fixed-dose products containing the same two active ingredients are listed, approved, and regulated by multiple international drug authorities, including the EMA (Europe) and MHRA (UK).


Q: Can Tozy cause changes in vision?

A: Officially documented adverse reaction lists for Tozy's active ingredients do not generally include changes in vision as a common effect. However, some regulatory documents for similar combination products have noted Blurred Vision as an effect of unknown incidence.


Q: How is Tozy different from a supplement for the same condition?

A: Tozy is regulated as a pharmaceutical drug product and an over-the-counter medicine with officially approved uses, manufacturing standards, and labeling. Unlike dietary supplements, the product’s composition, purity, and strength are mandated and continuously monitored by regulatory authorities.


Q: What if I'm already taking medication for anxiety/depression, can I take Tozy?

A: Official interaction warnings include specific restrictions with agents like Monoamine Oxidase Inhibitors (MAOIs), which are sometimes used to treat depression. For all other prescription or nonprescription medications, regulatory labels indicate that patients are encouraged to inform their healthcare provider about all for review.


Q: What is the most serious risk associated with Tozy?

A: The most serious risks cited in regulatory labeling are associated with the Acetaminophen component and include the potential for Acute Liver Failure (particularly with overdose or heavy alcohol use) and Severe Skin Reactions (e.g., Stevens-Johnson Syndrome). These events are generally classified as very rare.

How should Tozy be stored and disposed of?

How to Store and Dispose of Tozy?

Tozy (Acetaminophen/Caffeine tablets) must be stored according to official regulatory labeling to maintain stability and ensure safety.

Official Storage Requirements

Storage Component Requirement
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Environment Protect from excess heat and moisture; keep the product from freezing and away from direct light.
Container Keep the medication in the original container, tightly closed.
Child Safety Must be kept out of the sight and reach of children at all times.

Disposal Protocols

Unused or expired Tozy should be disposed of via an authorized drug take-back program where available. If a take-back program is not accessible, official instructions require mixing the product with an undesirable substance (e.g., used coffee grounds) and placing it in a sealed container before discarding it in the household trash. The medication must not be flushed down the toilet or disposed of in wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tozy found in:

A-Z Index: